3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Chairman & Managing Director, Dhirendra Dubey, wrote to shareholders after rescheduling a conference call from February 18 to February 21 due to laryngitis. He shared highlights from the MEDLAB (WHX) Dubai exhibition held February 9–14, where the company promoted its TRUPCR molecular diagnostics brand and received strong recognition from global players and Indian lab visitors. The management identified 2–3 potential M&A targets at the event, though they cautioned that such leads often fade. Subsidiary Coris, which focuses on antimicrobial resistance (AMR) testing with its RESIST-5 brand, also drew good inquiries at the show.
No immediate financial impact. The letter offers qualitative brand-building and M&A scouting updates rather than hard numbers, so investors should await the scheduled call on February 21 for any concrete business or guidance details.